No article text was recorded for this version.
HIV vaccine development challenge
Version 1 of 118 papers20 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
- Blog: Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
- Blog: In danger: HIV vaccine research and development in Europe
- Blog: Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
- Blog: Screening helper T lymphocyte epitopes based on IFN-γ/IL-10 ratio for developing a novel multi-epitope vaccine candidate using Wolbachia surface protein as an adjuvant against visceral leishmaniasis
- Blog: Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
- Blog: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
- Blog: Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
- Blog: Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
- Blog: Analysis of the Interaction Between the Attenuated HSV-1 Strain M6 and Macrophages Indicates Its Potential as an Effective Vaccine Immunogen
- Blog: Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
- Blog: Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
- Blog: Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women
- Blog: The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
- Blog: ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost
- Blog: Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates
- Blog: Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach
- Blog: A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_hiv_vaccine_development_challenge_7bd43ddc,
title = {HIV vaccine development challenge},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/hiv-vaccine-development-challenge/rdr_7bd43ddc416f46018f69c316a5268314},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_hiv_vaccine_development_challenge_7bd43ddc_v1,
title = {HIV vaccine development challenge},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/hiv-vaccine-development-challenge/rdr_7bd43ddc416f46018f69c316a5268314/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}